Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 2 clients • 5 examiners • 5 art units • 0 of 5 (0%) have an AI response strategy ready
Purdue - Flaster Greenberg P.C. has managed 39 career applications in the Biotechnology & Pharmaceuticals technology area. The firm has achieved a resolved allowance rate of 50.0. Prosecution involves an average of 4.0 office actions per allowance to reach a final outcome.
Currently, the firm is overseeing 5 pending office actions. This active docket is part of a history that includes 39 career applications. The 50.0 resolved allowance rate serves as a performance metric for the firm's work in the Biotechnology & Pharmaceuticals sector.
An average of 4.0 office actions per allowance indicates the engagement with patent examiners. With 5 pending office actions currently active, the firm continues to prosecute applications within its technical field, building on its previous experience.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| Multi-statute (no §101) | 4 (80%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FUBARA, BLESSING M | 1 | 62.2% | +34.1% |
| DAVIS, BRIAN J | 1 | 84.8% | -3.9% |
| OGUNBIYI, OLUWATOSIN A | 1 | 63.8% | +41.2% |
| WORSHAM, JESSICA N | 1 | 56.6% | +56.4% |
| COUGHLIN, MATTHEW P | 1 | 71.3% | +12.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18123018 | Circularly Recyclable Polymers Featuring Topochemically Elongated Carbon-Carbon Bonds | COUGHLIN, MATTHEW P | 36d overdue |
| 18550036 | NOVEL VACCINE FORMULATIONS FOR MYCOBACTERIUM TUBERCULOSIS AND USE OF THEREOF | OGUNBIYI, OLUWATOSIN A | 17d overdue |
| 18285439 | IMMUNOFUNCTIONAL CARRIER, METHODS OF USES, AND COMPOSITION MATTERS AS AN ANTITUMOR IMMUNOTHERAPY | DAVIS, BRIAN J | 3d overdue |
| 18702531 | NANOPARTICLE-BASED ABUSE-DETERRENT FORMULATIONS AND METHODS OF MAKING AND USING | FUBARA, BLESSING M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18034969 | NON-CATIONIC SOFT POLYPHENOL NANOCAPSULES FOR EFFECTIVE SYSTEMIC DELIVERY OF SMALL INTERFERING RNA (siRNA) FOR CANCER TREATMENT | WORSHAM, JESSICA N | 44d overdue |
| 18123018 | Circularly Recyclable Polymers Featuring Topochemically Elongated Carbon-Carbon Bonds | COUGHLIN, MATTHEW P | 36d overdue |
| 18550036 | NOVEL VACCINE FORMULATIONS FOR MYCOBACTERIUM TUBERCULOSIS AND USE OF THEREOF | OGUNBIYI, OLUWATOSIN A | 17d overdue |
| 18702531 | NANOPARTICLE-BASED ABUSE-DETERRENT FORMULATIONS AND METHODS OF MAKING AND USING | FUBARA, BLESSING M | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Purdue University | 4 |
| Houston Methodist | 1 |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| 1614 | 1 |
| 1645 | 1 |
| 1615 | 1 |
| 1626 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18702531 | NANOPARTICLE-BASED ABUSE-DETERRENT FORMULATIONS AND METHODS OF MAKING AND USING | Purdue Research Foundation | FUBARA, BLESSING M | 1613 | §103§112 | Non-Final OA | — | Pending | Apr 18, 2024 |
| 18285439 | IMMUNOFUNCTIONAL CARRIER, METHODS OF USES, AND COMPOSITION MATTERS AS AN ANTITUMOR IMMUNOTHERAPY | Purdue Research Foundation | DAVIS, BRIAN J | 1614 | §102§112 | Non-Final OA | 3d overdue | Pending | Oct 03, 2023 |
| 18550036 | NOVEL VACCINE FORMULATIONS FOR MYCOBACTERIUM TUBERCULOSIS AND USE OF THEREOF | Houston Methodist Research Institute | OGUNBIYI, OLUWATOSIN A | 1645 | §102§103§112 | Final Rejection | 17d overdue | Pending | Sep 11, 2023 |
| 18034969 | NON-CATIONIC SOFT POLYPHENOL NANOCAPSULES FOR EFFECTIVE SYSTEMIC DELIVERY OF SMALL INTERFERING RNA (siRNA) FOR CANCER TREATMENT | Purdue Research Foundation | WORSHAM, JESSICA N | 1615 | §103 | Final Rejection | 44d overdue | Pending | May 02, 2023 |
| 18123018 | Circularly Recyclable Polymers Featuring Topochemically Elongated Carbon-Carbon Bonds | Purdue Research Foundation | COUGHLIN, MATTHEW P | 1626 | §102§112 | Non-Final OA | 36d overdue | Pending | Mar 17, 2023 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial50.0% of resolved applications prosecuted by Purdue - Flaster Greenberg P.C. were allowed, across 39 applications in USPTO records.
4.00 office actions per allowed application on average.
5 pending office actions as of October 2026, for 2 clients, before 5 examiners in 5 art units.
